Thank you for the comments and for the question. Of course, I monitor the use and the impact of the fund. It’s important not just to have a statement where we can say we’ve made a promise and we’ve delivered on it. We then need to make sure it’s doing what we thought it would do and providing that real benefit for individuals across the country. And, in doing that, there’ll be money for each health board. I want to ensure that every health board gets a proper share of the resource, but then has a proper expectation that they’ll deliver against that. This isn’t just money to go into the pot to do what they want with. That’s why it is going to be ring-fenced. That’s why there will be directions. That’s why we will be monitoring the use and the impact of the money.

The AWMSG process has been successful for us in Wales. At least 29 new medicines have been available much quicker than NICE have been able to do for the whole of the UK as well. So, that’s a real benefit in our ability to have medication available on an earlier basis in Wales. This will add to that as well. Part of the challenge has been on delivering patient access schemes—the point about the benefit and the cost between the public purse, the company and the individual who could benefit from the treatment. That does mean that I have difficult conversations sometimes with the pharmaceutical industry. I want to see that improve as we go through.

The information that I’ve had about the issue you raised about Roche and Avastin has been about the challenge over the provision of information, the time that should be provided, the ability and the willingness to sign up to a patient access scheme, but then also about the conversations about how that information is transferred between the two. I’d be very happy to have a conversation with you to respond to information about what’s happened in a particular case, but also for the future as well, because I do want to see that maturity in relation to what I’ve described being developed and continuing for the future. Because, as I say, it’s in the interests of the industry; but equally, it’s in the interests of the NHS and the patients that we’re here to serve as well.